This notice ("Notice") is sent to you as a shareholder ("Shareholder") of Orchard US Small Cap Value Fund (the "Fund"), a sub-fund of Candoris ICAV (the "ICAV"). It is important and requires your immediate attention. If you do not fully understand the contents of the Notice, or if you are in any doubt as to the action to be taken, you should immediately consult your stockbroker, solicitor or attorney or other professional advisor.

The directors of the ICAV (the "**Directors**") have taken all reasonable care to ensure that, as at the date of this Notice, the information contained in this Notice is in accordance with the facts and does not omit anything likely to affect the import of such information. The Directors accept responsibility for the information contained in this Notice.

NOTICE TO SHAREHOLDERS

OF

ORCHARD US SMALL CAP VALUE FUND

A SUB-FUND OF

CANDORIS ICAV

(an umbrella type Irish collective asset-management vehicle with segregated liability between sub-funds governed by the laws of Ireland and authorised by the Central Bank of Ireland pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011, as amended)

DATED 24 April 2024

If you sold or otherwise transferred your holding in the Fund, please send this Notice to the stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee. Please note that, unless otherwise indicated, all capitalised terms in this Notice shall have the same meaning as described in the prospectus for the ICAV dated 22 July 2021, the Addendum to the

Prospectus dated 19 January 2023 and the Existing Fund Supplement dated 19 January 2023 (together, the "Prospectus").

Candoris ICAV

(an umbrella fund with segregated liability between sub-funds)

24 April 2024

Dear Shareholder,

We are writing to you in your capacity as a holder of Shares in the Fund, a sub-fund of the ICAV, to inform you of certain amendments to the supplement of the Fund (the "**Supplement**") as detailed below.

1. AMENDMENT OF THE SUPPLEMENT

The Prospectus and instrument of incorporation ("**IOI**") of the ICAV permit the Directors to apply a redemption gate where the repurchase requests on any dealing day are more than ten percent of the net asset values of shares in a sub-fund of the ICAV in issue at a valuation point for that dealing day. The "*Maximum Repurchase Amount*" section of the Prospectus states:

"The Directors following consultation with the Manager will have the option to limit the number of Shares of any Fund repurchased on any Dealing Day (other than upon the termination of the Fund) to 10% of the total Net Asset Value of that Fund on that Dealing Day and, in conjunction with such limitation, to pro rata limit the number of Shares repurchased by any Shareholder on such Dealing Day so that all Shareholders wishing to have Shares of that Fund repurchased on that Dealing Day realise the same proportion of such Shares. In the event the Directors elect to limit the number of Shares repurchased on such date to 10% of the Net Asset Value of the Fund, a Shareholder may not be able to repurchase on such Dealing Day all the Shares that it desires to repurchase and Shares not repurchased, but which would otherwise have been repurchased, will be carried forward for redemption on each subsequent Dealing Day, on a pro rata basis, until all Shares relating to the original repurchase request have been repurchased. Investors should review this Prospectus and the relevant Supplement to ascertain whether and how such provisions apply."

The Supplement of the Fund notes the Directors shall not exercise their option to limit the number of shares in the Fund which may be repurchased on any dealing day. It is proposed to update the Supplement of the Fund to remove this passage. An updated version of the Supplement showing the proposed amendments can be found at Appendix 1. The text in red is the text which is proposed be deleted from the Supplement.

The rationale for the proposed update to the Supplement is to provide greater flexibility to the ICAV with respect to the use of liquidity management tools, and the ability to apply a redemption gate in the circumstances outlined in the Prospectus and IOI accords with standard market practice.

The update to the Supplement will not result in an increase in the fees and expenses of the Fund as set out in the Supplement.

2. EFFECTIVE DATE

Please note that the changes outlined above are subject to the approval of the Central Bank of Ireland (the "**Central Bank**") and an updated Supplement will be filed with the Central Bank for review.

The proposed changes to the Supplement will be implemented on or around 9 May 2024 (the "Effective **Date**") subject to the approval of the Central Bank and inclusion of any other minor amendments, which may be requested by the Central Bank. The final version of the Supplement, once noted by the Central Bank, will be available on www.candoris.nl

3. ACTION TO BE TAKEN

Please note that this Notice requires no action on your part as the aforementioned changes do not require Shareholder approval. You may redeem your Shares at any in accordance with the procedures set out in the Prospectus.

Yours faithfully,

cump

Director For and on behalf of Candoris ICAV

Appendix 1

each Dealing Day and the Valuation Point shall always be after the Dealing Deadline. This Supplement shall be updated in the event of a change of the Valuation Point.

No Maximum Repurchase Amount on any Dealing Day

The Directors shall not exercise their option to limit the number of Shares of the Fund which may be repurahased on any Dealing Day as provided for under the Prospectus such that the IGAV shall repurahase on any Dealing Day all the Shares that any Shareholders desire to have repurahased on such Dealing Day.

13. FEES AND EXPENSES

The fixed fees payable by the Fund are currently as set out below. The fees and out-of-pocket expenses of the Manager, the Investment Manager, the Advisory and Marketing Support Agent, the Administrator, the Depositary, the relevant portion of the Directors' fees payable by the ICAV which have been allocated to the Fund, administrative expenses of the Fund, sub-depositary fees (which shall be charged at normal commercial rates), the regulatory levy of the Fund, establishment costs, registration costs and other administrative expenses shall be discharged out of the Fixed TER specified below. The establishment costs of the Fund are €20.000. The establishment costs will be amortised over a period of three years.

The Fixed Management Fee covers the fees and out-of-pocket expenses of the Manager, Investment Manager and Advisory and Marketing Support Agent. The other fees and expenses listed above will be paid out of the Fixed Service Fee.

In circumstances where the other fees and expenses accrued by the Fund, which are listed above as being paid out of the Fixed Service Fee, exceed the Fixed Service Fee set out below, those excess other fees and expenses shall be discharged from the Fixed Management Fee payable out of the assets of the Fund before it is paid to the Manager, Investment Manager and Advisory and Marketing Support Agent and the amount remaining for payment to such parties shall be reduced accordingly.

For the avoidance of doubt, the Fixed Management Fee and the Fixed Service comprising the Fixed TER specified below are payable out of the assets of the Fund at the levels specified below in all cases, including for example where the fees and out-of-pocket costs and expenses of the Manager, Investment Manager and Advisory and Marketing Support Agent are less than the Fixed Management Fee and/or where the other fees, costs and expenses listed above as being paid out of the Fixed Service Fee are less than the Fixed Service Fee.

	Class I1	Class I2	Class I3	Class I2 Euro	Class Retail
Fixed Management Fee	0.95% of NAV	0.85% of NAV	0.79% of NAV	0.85% of NAV	1.50% of NAV
Fixed Service Fee	0.20% of NAV	0.20% of NAV	0.20% of NAV	0.20% of NAV	0.20% of NAV
Fixed TER	1.15% of NAV	1.05% of NAV	0.99% of NAV	1.05% of NAV	1.70% of NAV

The Fixed Management Fee and Fixed Service Fee will accrue daily and are payable quarterly in arrears out of the assets of the Fund.

This section should be read in conjunction with the section entitled Fees and Expenses in the Prospectus.

17828048.117828048.2.C7034.103024

Directors: Conor Hoey (Irish), Brian Dunleavy (Irish), Dirk (Rick) Van De Kamp (Dutch), Martijn Van Vliet (Dutch) Registered Office: 35 Shelbourne Road, Ballsbridge, Dublin 4, Ireland Registration Number: C165457